$MTVA News

MetaVia Highlights New Phase 1 Data On DA-1726, Dual Oxyntomodulin Analog Agonist Targeting GLP1R And GCGR, In Late-Breaking Poster Presentation At EASL 2026

Why MetaVia Stock Is Surging On Friday?

Why MetaVia Stock Is Falling On Thursday?

MetaVia Announces Publication Of New Preclinical Research Supporting The Anti-Fibrotic Potential Of Vanoglipel In the Journal Biomolecules & Therapeutics

HC Wainwright & Co. Reiterates Buy on MetaVia, Maintains $20 Price Target

MetaVia Q1 EPS $(0.79) Misses $(0.74) Estimate

MetaVia To Present Obesity Drug DA-1726 Data At EASL Congress 2026 In Barcelona

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

MetaVia Says First Patient Dosed In Part 3 Of Phase 1 Clinical Trial Evaluating DA-1726, Dual Oxyntomodulin Analog Targeting Both GLP-1 And Glucagon Receptors

MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026…

HC Wainwright & Co. Maintains Buy on MetaVia, Lowers Price Target to $20

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate

OTC Markets Hosts Virtual Investor Presentation with H.H. Kim, CEO and President of MetaVia, and David Bautz, PhD, Senior Analyst at Zacks SCR

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

Institutional Review Board At Clinical Pharmacology Of Miami Approves MetaVia Phase 1 Part 3 Clinical Trial Of DA-1726.

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

MetaVia Announces Comprehensive Global IP Portfolio Supporting Vanoglipel, Orally Available G-Protein-Coupled Receptor 119 Agonist

MetaVia Announces Global IP Portfolio Supporting Vanoglipel

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum